Bright Minds Biosciences ... (DRUG)
33.51
-0.59 (-1.73%)
At close: Apr 24, 2025, 3:59 PM
33.05
-1.36%
Pre-market: Apr 25, 2025, 08:00 AM EDT
-1.73% (1D)
| Bid | 33.05 |
| Market Cap | 236.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.06M |
| EPS (ttm) | -0.15 |
| PE Ratio (ttm) | -223.37 |
| Forward PE | -11.54 |
| Analyst | Buy |
| Ask | 35 |
| Volume | 22,148 |
| Avg. Volume (20D) | 45,816 |
| Open | 34.69 |
| Previous Close | 34.10 |
| Day's Range | 33.37 - 34.39 |
| 52-Week Range | 0.93 - 79.02 |
| Beta | 1.02 |
About DRUG
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Bra...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 22, 2021
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol DRUG
Website https://brightmindsbio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for DRUG stock is "Buy." The 12-month stock price forecast is $85, which is an increase of 153.69% from the latest price.
Stock Forecasts4 months ago
-1.24%
Bright Minds Biosciences shares are trading higher...
Unlock content with
Pro Subscription
6 months ago
+1.72%
Bright Minds Biosciences shares are trading higher after the company announced a collaboration with Firefly Neuroscience to provide a full analysis of the EEG data in the BREAKTHROUGH study.
